Smart for Life (SMFL) $0.43 on Track to Close Pending Acquisition of Ceautamed Worldwide.
Has Smart for Life Found a Base at $0.45? Market Action Aside, We Think So. Report Out Monday.
Revive’s Quarterly Report, Discussion, and a Video!
With 5,000 hospitalizations reported daily (150,000 a month), contracting Covid is not something to be taken lightly - after you get it....
Revive Therapeutics Gains 25% on Positive FDA Comments.
The Company stated yesterday that it "has received positive comments from the FDA in regard to the Company’s request to determine and...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...
Smart for Life (SMFL) Teams up With Diamond Creek Capital
IPO Buyers Liked it at $5.00. We Liked it at $0.85. We Love it at $0.55.
LIVE...
Interview: Smart for Life (SMFL) CEO A.J. Cervantes.
Excellent interview. We were at the Noble Investor Conference to see it live. And we were at the manufacturing plant this Friday....
New Report: Lion Group Holdings (LGHL) Initiating Coverage.
Massive Long-Term Potential from Singapore based Rising Fintech Star.
A Fintech that nearly 'has it all' reported impressive...
Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...
We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10...
Smart For Life to Present at The Noble Capital Markets Eighteenth Annual Investor Conference.
MIAMI, April 14, 2022 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a global leading...
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
Latest article
Smart for Life (SMFL) Capitulates?
We Are Long Term Bullish on Smart for Life. After a Volatile Post IPO Trading, we may Have Seen the Bottom....
Althira (ATHA) $2.50, is Latest Alzheimer’s Trial Victim. Down 70%
Nearly 100 Alzheimer’s programs have failed in the past decade.
Biotech investors should study or at least become...
Novogratz Remains Steadfast on Crypto, Says Wait Until Next Year (Bloomberg)
Great call. This was actually from Late 2018.
(Bloomberg) — Billionaire investor Michael Novogratz is resolute when it...
